Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Further Insights Into Efficacy and Safety of Tumor Necrosis Factor-Inhibitors

Session Type: ACR Abstract Submissions
Tuesday, November 8, 2011: 4:30 PM-6:00 PM
W375a (McCormick Place West)
SessionSelect
Moderators: Richard W. Martin, MA, MD, Michigan State University College of Human Medicine and John J. Cush, MD, Baylor Research Institute
Papers:
4:30 PM
RA, Anti-TNF Therapy, and Risk of Malignant Melanoma-a Nationwide Population-Based Study From Sweden
Pauline Raaschou1, Julia F. Simard2, Martin Neovius2, Marie Holmqvist2, Jonas Eriksson2, Johan Askling2 and the ARTIS studygroup3, 1Clinical Pharmacology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Karolinska Institutet
4:45 PM
Opportunistic Infections in Patients Exposed to Anti-Tumour Necrosis Factor Therapy: Results From the British Society for Rheumatology Biologics Register
James B. Galloway1, Audrey SL Low1, Louise K. Mercer1, William G. Dixon1, Andrew Ustianowski2, Mark Lunt1, Kath D. Watson1, British Society for Rheumatology Biologics Register (BSRBR) control centre consortium3, Kimme L. Hyrich1, Deborah PM Symmons1 and . on behalf of the BSRBR1, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2University of Manchester, Manchester, United Kingdom, 3British Society for Rheumatology, London, United Kingdom
5:00 PM
The Risk of Solid Cancer in Patients Receiving Anti-Tumour Necrosis Factor Therapy for Rheumatoid Arthritis for up to 5 Years: Results From the British Society for Rheumatology Biologics Register
Louise K. Mercer1, James B. Galloway1, Audrey SL Low1, Kath D. Watson1, Mark Lunt1, William G. Dixon1, British Society for Rheumatology Biologics Register (BSRBR) control centre consortium1, Deborah PM Symmons1, Kimme L. Hyrich1 and On behalf of the BSRBR2, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2British Society for Rheumatology, London, United Kingdom
5:15 PM
Safety of Infliximab Therapy in Rheumatoid Arthritis Patients with Pre-Existing Hepatitis B Virus Infection
Xuewu Zhang1, Xia Liu2, Yuan An1, Ying Ning1 and Zhanguo Li1, 1Peking University People's Hospital, Beijing, China, 2China-Japan Friendship Hospital, Beijing, China
5:30 PM
FUNCTIONAL MRI (FMRI) IS Much FASTER In Detecting RAPID Symptom CONTROL by Certolizumab-Pegol In PATIENTS with RA THAN the Conventional MRI
Juergen Rech1, Stephanie Finzel1, Silke Kreitz1, Matthias Englbrecht1, Arnd Doerfler1, Marc Saake1, Andreas Hess1 and Georg Schett2, 1University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
5:45 PM
Etanercept Induces a Decrease in Left Ventricular Mass in Patients with Rheumatoid Arthritis
Claire Daien1, Pierre Fesler1, Vincent Daien2, Guilhem du Cailar1, Anne-Marie Dupuy1, Jean-Paul Cristol1, Jean Ribstein1, Bernard G. Combe1 and Jacques Morel1, 1Hopital Lapeyronie, Montpellier, France, 2Hopital Gui de Chauliac, Montpellier, France
See more of: ACR Abstract Submissions

To see other sessions for this day, use the date buttons to the left.